Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy
Breast Cancer
About this trial
This is an interventional diagnostic trial for Breast Cancer focused on measuring Breast Cancer, Armpit lymph nodes Cancer
Eligibility Criteria
Inclusion Criteria:
- Eligible patients will include any patients with biopsy-proven breast cancer and biopsy-proven axillary lymph node metastases at Beth Israel Deaconess Medical Center who are candidates for Neoadjuvant Chemotherapy or Neoadjuvant Endocrine therapy.
- A core needle biopsy or fine needle aspiration is acceptable for diagnosis of metastatic disease in lymph nodes.
- Patients will be identified as possible participants in the Radiology Imaging suites and Breast Surgery Clinics.
Exclusion Criteria:
-Patients with inflammatory breast cancer or distant metastases will be excluded from participating in this study
Sites / Locations
Arms of the Study
Arm 1
Experimental
Axillary Lymph Node Sampling Clip
Axillary Lymph Node Biopsy -- Axillary lymph node sampling with clip placement into the sampled lymph node. After the tissue sampling of any suspicious nodes, a marker clip will be placed to allow for intra-operative identification of the biopsied nodes. Neoadjuvant therapy at the discretion of the treating Medical Oncologist. Once Neoadjuvant therapy is completed, surgery in the form of either Lumpectomy or Mastectomy is performed. Wire-localization of the clipped node on the day of surgery. Lymphatic mapping performed with either radiocolloid and/or blue dye. Sentinel lymph node biopsy will be performed on the day of surgery. --- If the clipped node which contains the wire is not part of this sentinel lymph node specimen, then it will be removed separately and be sent to Pathology as a separate specimen. Axillary lymph node dissection as is the standard of care.